American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Neuropsychopharmacology (1995) 12 347-349.

alpha2 Adrenergic Agonists Prevent MK-801 Neurotoxicity

Nuri B Farber MD, John Foster BA, Nadine L Duhan BS and John W Olney MD
From Department of Psychiatry, Washington University Scchool of Medicine, St. Louis, MO

Correspondence: Nuri B Faber, MD, Department of Psychiatry, Washington University School of Medicine, 4940 Children's Place, St. Louis, MO 63110

ABSTRACT

Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor are of considerable interest for various neurotherapeutic purposes, including preventing neuronal degeneration in stroke and CNS trauma, suppressing neuropathic pain and preventing the development of tolerance to opiate analgesics. Unfortunately, NMDA antagonists can cause potentially serious side effects, including acute neurodegenerative changes in corticolimbic regions of the adult rat brain and psychotic reactions in adult humans. We have been investigating the mechanisms underlying the neuropathological changes in rat brain and exploring methods of suppressing or preventing such changes. Here we report that alpha2 adrenergic agonists can prevent NMDA antagonist neurotoxicity. Therefore, administering alpha2 adrenergic agonists together with NMDA antagonists may be a valuable strategy for preventing adverse side effects of NMDA antagonists and making these agents safer for various neurotherapeutic purposes.

Keywords: Clonidine; α2 adrenergic receptor; Neurotoxicity; MK-801; Phencyclidine; NMDA antagonists
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1995 by the American College of Neuropsychopharmacology